Related Experiment Video

Updated: Oct 22, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.8K

The RhoA dependent anti-metastatic function of RKIP in breast cancer

Gardiyawasam Kalpana1, Christopher Figy1, Jingwei Feng1,2

  • 1Department of Cancer Biology, College of Medicine and Life Sciences, University of Toledo, Health Science Campus, Toledo, OH, 43614, USA.

Scientific Reports
|September 1, 2021
PubMed

Insights

Raf-1 kinase inhibitor protein (RKIP) suppresses cancer metastasis by activating RhoA. This mechanism enhances E-cadherin localization and reduces CCL5 expression, highlighting RKIP

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Cell Signaling

Background:

  • Raf-1 kinase inhibitor protein (RKIP) is known to inhibit the MAPK pathway and suppress cancer metastasis.
  • The precise molecular mechanisms by which RKIP exerts its anti-metastatic effects remain incompletely understood.
  • RhoA GTPase activity is context-dependent, influencing cell movement and metastasis.

Purpose of the Study:

  • To elucidate the molecular mechanism by which RKIP inhibits cancer cell invasion and metastasis.
  • To investigate the role of RhoA GTPase in RKIP-mediated anti-metastatic functions.
  • To determine how RKIP targets RhoA and its downstream effectors.

Main Methods:

  • Investigated RKIP's effect on RhoA activation in cancer cells.
  • Utilized Erk2 and GEF-H1 in mechanistic studies.
  • Assessed E-cadherin membrane localization and CCL5 expression levels.

Main Results:

  • RKIP was shown to inhibit cancer cell invasion and metastasis by stimulating RhoA's anti-tumorigenic functions.
  • RKIP activates RhoA in a manner dependent on Erk2 and GEF-H1.
  • This activation leads to enhanced E-cadherin membrane localization and decreased CCL5 expression.

Conclusions:

  • RKIP inhibits cancer metastasis through the activation of RhoA.
  • The Erk2/GEF-H1 pathway mediates RKIP's effect on RhoA.
  • RKIP's action on RhoA impacts key regulators of cell adhesion (E-cadherin) and inflammation/metastasis (CCL5).

More Related Videos

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

8.4K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.2K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
4.4K
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.5K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.1K